Results 31 to 40 of about 15,931 (229)

Methodologic issues in trials of antiemetics.

open access: yes, 1984
Studies of antiemetics require consideration of methodologic issues that may not be of concern in trials of antineoplastics. This paper illustrates how the strength of the results of these studies can be affected by (1) the types of patients studied, (2)
J L Pater, A R Willan
core   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink   +9 more
wiley   +1 more source

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

open access: yesCancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna   +5 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore   +16 more
wiley   +1 more source

Efficacy of antiemetics in patients receiving XELOX – a single-centre, prospective study

open access: yes, 2011
Background: XELOX (combination therapy of capecitabine and oxaliplatin) is known to cause nausea and vomiting, despite adequate administration of antiemetics.
A. Chan   +10 more
core   +1 more source

Statistical appendix for the Meta-analysis "Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents"

open access: yes, 2022
Statistical analysis for the Cochrane GUT Meta-analysis update: "Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents"
Borges do Nascimento, Israel Junior   +2 more
core   +1 more source

Segmental Hair Analysis of Diphenhydramine and Cyclizine Following a Single Dose

open access: yesDrug Testing and Analysis, EarlyView.
A single oral dose of diphenhydramine and cyclizine can be quantified in human head hair for a minimum of 5 months and, in certain cases, for up to 1 year following intake. Among 12 study participants, the measured concentrations ranged from 0 to 610 pg/mg within 1 year post‐intake.
Jan Bílek   +3 more
wiley   +1 more source

Do antiemetics attenuate the behavioural responses of sheep to simulated ship motion?

open access: yes, 2020
During actual and simulated ship transport, vessel roll (sideways) and heave (vertical) movements produce behavioural responses in sheep, typically positional and feeding changes.
Santurtun, Eduardo   +2 more
core   +1 more source

Complete response rates, requirement of rescue antiemetics, and satisfaction score after surgery.

open access: yes, 2018
Complete response rates, requirement of rescue antiemetics, and satisfaction score after surgery.
Jung-Hee Ryu (4339798)   +4 more
core   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

open access: yesInternational Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy